ARNA:NSD-Arena Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 99.99

Change

0.00 (0.00)%

Market Cap

USD 6.17B

Avg Analyst Target

USD 96.38 (-3.62%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Arena Pharmaceuticals Inc (ARNA) Stock Analysis:
Based on the Arena Pharmaceuticals Inc stock forecasts from 10 analysts, the average analyst target price for Arena Pharmaceuticals Inc is USD 96.38 over the next 12 months. Arena Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Arena Pharmaceuticals Inc is Slightly Bullish , which is based on 2 positive signals and 1 negative signals. At the last closing, Arena Pharmaceuticals Inc’s stock price was USD 99.99. Arena Pharmaceuticals Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +63.57% over the last year.

About

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerati ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

-2.05 (-0.31%)

USD71.36B 9.16 6.88
VRTX Vertex Pharmaceuticals Incorpo..

+3.10 (+1.23%)

USD64.54B 26.63 18.23
MRNA Moderna Inc

+5.67 (+4.12%)

USD54.78B 4.05 2.41
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+10.81 (+6.88%)

USD36.74B 3.67 1.75
SGEN Seagen Inc

-0.37 (-0.26%)

USD26.32B 55.02 44.86
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
GMAB Genmab A/S

+0.84 (+2.84%)

USD19.31B 46.16 5.06
ARGX argenx SE

+15.26 (+5.01%)

USD17.59B N/A N/A
INCY Incyte Corporation

+0.95 (+1.29%)

USD16.26B 17.19 22.08

ETFs Containing ARNA

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

+0.35 (+6.15%)

USD0.67B
ROGS Hartford Multifactor Glob.. 0.00 % 0.34 %

N/A

USD0.02B
SBIO ALPS ETF Trust - ALPS Med.. 0.00 % 0.50 %

+0.41 (+1.60%)

USD0.11B
VALX Validea Market Legends ET.. 0.00 % 0.79 %

N/A

USD0.01B
XBI SPDR S&P Biotech ETF 0.00 % 0.35 %

+1.53 (+2.25%)

USD5.73B
MJ ETFMG Alternative Harvest.. 0.00 % 0.75 %

+0.16 (+2.10%)

USD0.57B
MJX ETFMG Alternative Harvest.. 0.00 % 0.00 %

N/A

N/A
CBDX:LSE The Medical Cannabis and .. 0.00 % 0.80 %

-0.10 (-1.38%)

N/A
FLWG:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-7.38 (-2.48%)

N/A
FLWR:LSE Rize UCITS ICAV - Rize Me.. 0.00 % 0.65 %

-0.06 (-1.70%)

N/A
BLUM:XETRA Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

-0.06 (-1.65%)

USD0.03B
CBSX:XETRA Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

-0.10 (-1.54%)

USD0.02B
BLUM:F Rize Ucits ICAV - Rize Me.. 0.00 % 0.65 %

N/A

N/A
CBSX:F Hanetf ICAV - Hanetf Alte.. 0.00 % 0.80 %

N/A

N/A
DRUP:F Lyxor Index Fund - Lyxor .. 0.00 % 0.45 %

N/A

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.59% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.59% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 58.82% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 58.82% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 651.80% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 651.80% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 33.58% 75% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.58% 75% C 83% B
Risk Return Profile  
Volatility (Standard Deviation) 47.42% 54% F 28% F
Risk Adjusted Return 70.81% 95% A 87% B+
Market Capitalization 6.17B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 6.40 N/A N/A N/A N/A
Price/Book Ratio 9.16 N/A N/A N/A N/A
Price / Cash Flow Ratio -13.64 N/A N/A N/A N/A
EV/EBITDA 3.52 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -70.30% N/A N/A N/A N/A
Return on Invested Capital -68.19% N/A N/A N/A N/A
Return on Assets -34.53% N/A N/A N/A N/A
Debt to Equity Ratio 5.37% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 5.79 N/A N/A N/A N/A
Short Percent 11.32% N/A N/A N/A N/A
Beta 0.55 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.